OncoMatch/Clinical Trials/NCT04673942
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Is NCT04673942 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including AdAPT-001 and Checkpoint Inhibitor, Immune for solid tumor, adult.
Treatment: AdAPT-001 · Checkpoint Inhibitor, Immune — AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all conventional therapies considered appropriate by Investigator
who have received all conventional therapies considered appropriate by Investigator
Cannot have received: adenoviral therapy
Exception: except vaccination against infectious disease
Prior adenoviral therapy for any indication except vaccination against infectious disease
Cannot have received: chemotherapy
Exception: within 14 days of study treatment
Chemotherapy or immunotherapy within 14 days of study treatment
Cannot have received: immunotherapy
Exception: within 14 days of study treatment
Chemotherapy or immunotherapy within 14 days of study treatment
Lab requirements
Blood counts
Absolute neutrophil count > 1,500 cells/mm3; Platelet count > 75,000/mm3; Hemoglobin (HGB) ≥ 8.0 g/dL
Kidney function
Serum Creatinine < 1.5 x ULN
Liver function
Bilirubin < 1.5 x ULN; AST (SGOT) and ALT (SGPT) < 3.0 x ULN; Alkaline Phosphatase < 2.5 x ULN
Subject has acceptable liver function at Screening...Subject has a Serum Creatinine < 1.5 x ULN...Subject has acceptable hematologic status at Screening...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- California Cancer Associates for Research and Excellence, cCARE · San Marcos, California
- Providence Saint John's Health Center · Santa Monica, California
- Cleveland Clinic · Cleveland, Ohio
- Mary Crowley Cancer Research · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify